- Home
- NKTR vs GSBD Comparison
NKTR vs GSBD Comparison
Compare NKTR & GSBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NKTR | GSBD |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 1994 | N/A |
Fundamental Metrics
Financial Performance| Metric | NKTR | GSBD |
|---|---|---|
| Price | $53.04 | $9.82 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 6 | 1 |
| Target Price | ★ $106.33 | $9.00 |
| AVG Volume (30 Days) | 613.8K | ★ 1.3M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | ★ 12.88% |
| EPS Growth | N/A | ★ 69.72 |
| EPS | N/A | ★ 1.14 |
| Revenue | $62,600,000.00 | ★ $383,307,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.70 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.48 | $9.35 |
| 52 Week High | $66.92 | $13.45 |
Technical Indicators
Market Signals| Indicator | NKTR | GSBD |
|---|---|---|
| Relative Strength Index (RSI) | 43.87 | 45.82 |
| Support Level | $50.49 | $9.90 |
| Resistance Level | $59.23 | $10.15 |
| Average True Range (ATR) | 3.97 | 0.15 |
| MACD | -0.73 | 0.01 |
| Stochastic Oscillator | 15.58 | 31.75 |
Price Performance
Historical ComparisonAbout NKTR Nektar Therapeutics
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
About GSBD Goldman Sachs BDC Inc.
Goldman Sachs BDC Inc is a non-diversified, closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and, to a lesser extent, capital appreciation primarily through direct originations of secured debt, including the first lien, unitranche and second lien debt, and unsecured debt. It invests primarily in U.S. middle-market companies such as banks and the public debt markets. The company focuses on the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.